ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy-Reference-Cited by-同舟云学术

ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy

Published:2014-09-25 Issue:1 Volume:12 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Palomba Grazia,Atzori Francesco,Budroni Mario,Ombra MariaNeve,Cossu Antonio,Sini MariaCristina,Pusceddu Valeria,Massidda Bruno,Frau Barbara,Notari Francesca,Ionta MariaTeresa,Palmieri Giuseppe

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12967-014-0272-4.pdf

Reference41 articles.

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.

2. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page D, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002, 20: 3628-3636. 10.1200/JCO.2002.02.026.

3. Aapro MS: Neoadjuvant therapy in breast cancer: can we define its role?. Oncologist. 2001, 6 (Suppl. 3): 36-39. 10.1634/theoncologist.6-suppl_3-36.

4. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE: Efficacy of neoadjuvant cisplatin in triple negative breast cancer. J Clin Oncol. 2010, 28: 1145-1153. 10.1200/JCO.2009.22.4725.

5. Torrisi R, Cardillo A, Cancello G, Dellapasqua S, Balduzzi A, Ghisini R, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M: Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer. Clin Breast Cancer. 2010, 10: 483-488. 10.3816/CBC.2010.n.064.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Baş boyun kanserli hastalarda tek gen polimorfizmi ile sisplatin ve 5-FU tedavisine yanıt arasındaki ilişki;Turkish Journal of Clinics and Laboratory;2023-09-30

2. Breast cancer pharmacogenetics: a systematic review;Pharmacogenomics;2023-01

3. The Potential Predictors in Chemotherapy Sensitivity;Advances in Experimental Medicine and Biology;2021

4. Clinical Perspectives of ERCC1 in Bladder Cancer;International Journal of Molecular Sciences;2020-11-22

5. The Significant Interaction of Excision Repair Cross-complementing Group 1 Genotypes and Smoking to Lung Cancer Risk;Cancer Genomics - Proteomics;2020